GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » EPS without NRI

Hepion Pharmaceuticals (Hepion Pharmaceuticals) EPS without NRI : $-11.44 (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals EPS without NRI?

Hepion Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.44.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 35.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 63.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Hepion Pharmaceuticals's EPS without NRI or its related term are showing as below:

HEPA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.4   Med: 55   Max: 84.8
Current: 35.3

During the past 11 years, Hepion Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 84.80% per year. The lowest was -41.40% per year. And the median was 55.00% per year.

HEPA's 3-Year EPS without NRI Growth Rate is ranked better than
82.05% of 1298 companies
in the Biotechnology industry
Industry Median: 5.45 vs HEPA: 35.30

Hepion Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2023 was $-2.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.32.

Hepion Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2023 was $-2.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.32.


Hepion Pharmaceuticals EPS without NRI Historical Data

The historical data trend for Hepion Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals EPS without NRI Chart

Hepion Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.05 -41.78 -8.74 -11.54 -11.30

Hepion Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -3.47 -3.70 -2.78 -1.49

Competitive Comparison of Hepion Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, Hepion Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's PE Ratio without NRI falls into.



Hepion Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hepion Pharmaceuticals  (NAS:HEPA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hepion Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170